Polaryx Therapeutics Inc (PLYX) Stock Price, Quote & News

Company Profile

Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage n...

Industry: Biotechnology

Sector: Healthcare

Phone: 201 940 7236

Website: polaryx.com

Address:

South Tower, 140 E Ridgewood Avenue Suite 415, Paramus, United States

FrostyOrbit Aug. 29 at 7:27 PM

$PLYX Phase 2 trial expected to start in H2 2026 across CLN2, CLN3, Krabbe and Sandhoff disease...

0 · Reply

FrostyOrbit Aug. 29 at 7:25 PM

$PLYX is the lead drug candidate targeting multiple rare lysosomal diseases…

0 · Reply

prismmarketview Aug. 26 at 8:13 PM

$PLYX Polaryx Therapeutics plans to open SOTERIA in the fourth quarter, a Phase 2 basket trial testing PLX-200 across four rare pediatric lysosomal storage disorders at once. FDA clearance, Fast Track designation in all four indications and a $10 million financing are already in place. The trial is designed to show which of the four responds best, then shape where the program goes next. https://prismmarketview.com/?p=5730016&preview=true

0 · Reply

Deelam Aug. 24 at 8:03 PM

$PLYX ??

0 · Reply

Golferhack12 Aug. 17 at 7:13 PM

$PLYX this talk was $48 8 months ago and now they're talking about not surviving they only have 11 million in cash left hard to believe it doesn't look like it's going to make it

1 · Reply

Deelam Aug. 17 at 5:39 PM

$PLYX ?

0 · Reply

MurrayK Aug. 13 at 6:07 PM

$PLYX better than average volume today. Finally a move in the right direction.

0 · Reply

swapo1 Aug. 13 at 5:34 PM

$PLYX This is gonna be a mover

0 · Reply

ajmrtxl Aug. 13 at 3:57 PM

$PLYX 's latest squeeze play

0 · Reply

Deelam Aug. 13 at 11:05 AM

$PLYX Polaryx Therapeutics Price Target Announced at $6.00/Share by Raymond James How many price targets does this stock need to move up even a little bit? My word.

0 · Reply

Polaryx appoints Will Charlton as chief medical officer

2026-08-25T12:40:13.000Z - 7 days ago

Polaryx provides operational readiness update for SOTERIA trial

Aug 25, 2026, 8:30 AM EDT - 7 days ago

Polaryx Therapeutics Advances Operational Readiness for SOTERIA Phase 2 Basket Trial

2026-08-17T08:19:58.000Z - 15 days ago

Polaryx initiated with a Strong Buy at Raymond James

Aug 13, 2026, 7:00 AM EDT - 19 days ago

Polaryx Therapeutics Quarterly report: Q2 2026

Jul 31, 2026, 7:00 AM EDT - 4 weeks ago

Polaryx Therapeutics Slides: Corporate presentation

Jul 28, 2026, 8:00 AM EDT - 5 weeks ago

Polaryx Therapeutics Proxy statement: Proxy filing

Jul 28, 2026, 8:00 AM EDT - 5 weeks ago

Polaryx Therapeutics Proxy statement: Proxy filing

2026-07-27T10:45:35.000Z - 5 weeks ago

Polaryx initiated with a Buy at Lucid Capital

Jul 23, 2026, 8:00 AM EDT - 5 weeks ago

Polaryx Therapeutics Slides: Corporate presentation

2026-07-09T10:15:08.000Z - 7 weeks ago

Polaryx initiated with a Buy at H.C. Wainwright

May 28, 2026, 8:30 AM EDT - 3 months ago

Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial

May 15, 2026, 7:00 AM EDT - 3 months ago

Polaryx Therapeutics Quarterly report: Q1 2026

May 14, 2026, 9:15 AM EDT - 3 months ago

Polaryx Therapeutics Receives GHP Magazine's Healthcare & Pharmaceuticals Awards

May 8, 2026, 7:00 AM EDT - 4 months ago

Polaryx Therapeutics Slides: Corporate presentation

Apr 23, 2026, 8:30 AM EDT - 4 months ago

Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference

2026-04-21T12:59:55.000Z - 4 months ago

Polaryx receives U.S. FDA Fast Track Designation for PLX-200

Apr 21, 2026, 8:30 AM EDT - 4 months ago

Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial

Apr 15, 2026, 9:15 AM EDT - 4 months ago

Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care

Apr 1, 2026, 8:30 AM EDT - 5 months ago

Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference

Mar 24, 2026, 8:00 AM EDT - 5 months ago

Polaryx Therapeutics Annual report: Q4 2025

2026-03-17T12:51:50.000Z - 6 months ago

Polaryx’s PLX-200 granted FDA Fast Track Designation in LINCL/CLN2

Mar 17, 2026, 8:30 AM EDT - 6 months ago

Polaryx Therapeutics Receives FDA Fast Track Designation for PLX‑200 for Late‑Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease)

2026-03-12T15:10:39.000Z - 6 months ago

Polaryx Therapeutics, Inc trading resumes

2026-03-12T15:05:41.000Z - 6 months ago

Polaryx Therapeutics, Inc trading halted, volatility trading pause

Mar 12, 2026, 8:30 AM EDT - 6 months ago

Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events

Mar 6, 2026, 6:00 AM EST - 6 months ago

Polaryx Therapeutics Slides: Corporate presentation

2026-02-27T14:09:23.000Z - 6 months ago

Maxim starts Polaryx at Buy, sees PLX-200 as differentiated

2026-02-27T13:43:18.000Z - 6 months ago

Polaryx commits to patients with rare pediatric lysosomal storage disorders

Feb 27, 2026, 8:30 AM EST - 6 months ago

Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders

2026-02-27T13:15:01.000Z - 6 months ago

Polaryx initiated with a Buy at Maxim

2026-02-17T13:35:43.000Z - 7 months ago

Polaryx selects CRO for Soteria Phase 2 trial

Feb 17, 2026, 8:30 AM EST - 7 months ago

Polaryx Therapeutics Selects Contract Research Organization for SOTERIA Phase 2 Basket Trial

2026-02-10T13:35:26.000Z - 7 months ago

Polaryx announces pre-clinical data related to Soteria

Feb 10, 2026, 8:30 AM EST - 7 months ago

Polaryx Announces Key Pre-Clinical Data Related to SOTERIA at the 22nd Annual WORLDSymposium™

2026-02-06T15:20:14.000Z - 7 months ago

Polaryx Therapeutics, Inc. trading resumes

2026-02-06T15:10:13.000Z - 7 months ago

Polaryx Therapeutics, Inc. trading halted, volatility trading pause

2026-02-05T20:35:14.000Z - 7 months ago

Polaryx Therapeutics, Inc. trading resumes

2026-02-05T20:30:16.000Z - 7 months ago

Polaryx Therapeutics, Inc. trading halted, volatility trading pause

2026-02-05T13:45:44.000Z - 7 months ago

Polaryx appoints Mitchel Berger, Francis Braun, Charles Ryan to board

Feb 5, 2026, 8:30 AM EST - 7 months ago

Polaryx Therapeutics Welcomes New Members of the Board of Directors

2026-02-04T15:05:33.000Z - 7 months ago

Polaryx Therapeutics, Inc. trading resumes

2026-02-04T14:55:29.000Z - 7 months ago

Polaryx Therapeutics, Inc. trading halted, volatility trading pause

Feb 3, 2026, 8:30 AM EST - 7 months ago

Polaryx to Present Late-Breaker Data Related to SOTERIA at the 22nd Annual WORLDSymposium™ as Company Prepares for SOTERIA Trial Launch

Feb 2, 2026, 8:30 AM EST - 7 months ago

Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol “PLYX”

Jan 30, 2026, 8:00 AM EST - 7 months ago

Polaryx Therapeutics Announces Approval to List Common Stock on Nasdaq

FrostyOrbit Aug. 29 at 7:27 PM

$PLYX Phase 2 trial expected to start in H2 2026 across CLN2, CLN3, Krabbe and Sandhoff disease...

0 · Reply

FrostyOrbit Aug. 29 at 7:25 PM

$PLYX is the lead drug candidate targeting multiple rare lysosomal diseases…

0 · Reply

prismmarketview Aug. 26 at 8:13 PM

0 · Reply

Deelam Aug. 24 at 8:03 PM

$PLYX ??

0 · Reply

Golferhack12 Aug. 17 at 7:13 PM

$PLYX this talk was $48 8 months ago and now they're talking about not surviving they only have 11 million in cash left hard to believe it doesn't look like it's going to make it

1 · Reply

Deelam Aug. 17 at 5:39 PM

$PLYX ?

0 · Reply

MurrayK Aug. 13 at 6:07 PM

$PLYX better than average volume today. Finally a move in the right direction.

0 · Reply

swapo1 Aug. 13 at 5:34 PM

$PLYX This is gonna be a mover

0 · Reply

ajmrtxl Aug. 13 at 3:57 PM

$PLYX 's latest squeeze play

0 · Reply

Deelam Aug. 13 at 11:05 AM

$PLYX Polaryx Therapeutics Price Target Announced at $6.00/Share by Raymond James How many price targets does this stock need to move up even a little bit? My word.

0 · Reply

Paraplego Aug. 4 at 3:52 PM

$NWBO is waiting game and im fine with it while im waiting im investing in $PLYX 14th Avgust is close for News and some small gains

0 · Reply

lew0303 Jul. 31 at 1:47 PM

$PLYX still going up?

0 · Reply

z____b1 Jul. 31 at 1:18 PM

$PLYX Not Bad!

0 · Reply

Bkaytradez Jul. 31 at 8:28 AM

$PLYX sub 2$ entry already paying off 💰

0 · Reply

Bkaytradez Jul. 31 at 8:28 AM

$PLYX 👀

0 · Reply

Lowkeyoptions Jul. 30 at 8:53 PM

$PLYX offering closed on watch

0 · Reply

Yebego Jul. 29 at 6:18 PM

$AMIX $GSUN $NCRA $PLYX $SPRC

0 · Reply

HustlerTV Jul. 29 at 6:09 PM

$PLYX short squeeze incoming $20 fair value… $NCRA $GSUN $SPRC $AMIX on watch for power hour

0 · Reply

StockfatherOG Jul. 29 at 6:08 PM

$PLYX golden biotech opportunity. Multiple $7 Price targets.

0 · Reply

Deelam Jul. 28 at 3:34 AM

$PLYX Another initial coverage setting the PT at $7. https://uk.investing.com/news/stock-market-news/lucid-capital-initiates-polaryx-stock-with-buy-rating-on-rare-disease-therapy-potential-93CH-4789487

0 · Reply

MurrayK Jul. 27 at 3:27 PM

$PLYX Man, we bought a dud here. Will be another cash raise I’m sure before end of year. Was primed for a pump and dump which looks like the only thing that’ll save current investors. Otherwise we’ll likely be diluted out.

0 · Reply

focafoca99 Jul. 17 at 12:19 PM

$PLYX set its 2026 annual meeting for Sept. 10, to be held virtually.

0 · Reply

Market Cap	102.68M
Revenue (ttm)	0.00
Net Income (ttm)	-8.99M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	41,400
Avg Vol	108,092
Day's Range	N/A - N/A
Shares Out	49.85M
Stochastic %K	46%
Beta	N/A
Analysts	Strong Sell
Price Target	$7.67